TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06631989: A Phase I/II Multicenter, Open Label, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of WSD0922-FU in the Treatment of Advanced Non-small Cell Lung Cancer

Sponsor: Wayshine Biopharm, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,639,400

Rescue Site Savings

+$5,694,150

Unlock Full NCT06631989 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06631989 Rescue Dossier →